drugset / Trial / NCT01395004
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afuresertib | Small molecule | 125 mg | Oral |